TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00607438
Drug: Sorafenib (Nexavar)
Normalized name: sorafenib Oral Tablet [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally twice a day continuously (even during rest week) starting on Day 1.
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
Study: NCT00703755
Drug: Fenofibrate /Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fenofibrate placebo + metformin 850 mg bid (F0-M1700)
Study: NCT03996434
Drug: Gonadotropin
Normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: withholding gonadotropin administration for at least 24 hours
Study: NCT02833116
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02833116
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03128216
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for local infiltration and Transversals fascia block
Study: NCT03128216
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for Spinal Anesthesia
Study: NCT00920595
Drug: CEP-9722
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
Study: NCT00844064
Drug: AP 12009
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles
Study: NCT02456857
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01983774
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01274429
Drug: Peanut flour
Normalized name: Peanut flour
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
Study: NCT00810719
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
Study: NCT00810719
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
Study: NCT00313534
Drug: masoprocol
Normalized name: Masoprocol
DrugBank: Masoprocol (DB00179)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00101803
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01445938
Drug: arthemeter + lumefantrine (ACTs)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine (DB06708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00486538
Drug: ABT-869
Normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral dose daily.
Study: NCT00538824
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)
Study: NCT00538824
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Study: NCT00215267
Drug: praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04537923
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04537923
Drug: Insulin Lispro (U100)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00538824
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*
Study: NCT04564872
Drug: Linagliptin 5 mg QD
Normalized name: linagliptin 5 MG
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Study: NCT00103246
Drug: silicon phthalocyanine 4
Normalized name: silicones 4.7 MG
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
Study: NCT01258530
Drug: over-encapsulated oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg once
Study: NCT01258530
Drug: oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg once
Study: NCT02855684
Drug: Insulin glargine (U300)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02423980
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02855684
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02855684
Drug: Non-insulin antihyperglycemic drugs
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule/tablet~Route of administration: oral
Study: NCT00005834
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
Study: NCT00005834
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms 1 and 2: 40 mg/d PO days 1-4
Study: NCT02527798
Drug: Furosemide Cohort 1
Normalized name: furosemide 1 MG/ML
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study: NCT02527798
Drug: Furosemide Cohort 2
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study: NCT02527798
Drug: Furosemide Cohort 3
Normalized name: furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study: NCT04252612
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
Study: NCT03000374
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
Study: NCT03000374
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
Study: NCT00625898
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
Study: NCT00625898
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
Study: NCT00625898
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
Study: NCT00625898
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B
Study: NCT00625898
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study: NCT00625898
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study: NCT00887146
Drug: concomitant temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m\^2, orally daily
Study: NCT00887146
Drug: procarbazine
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 8-21: 60 mg/m\^2 orally
Study: NCT00887146
Drug: adjuvant temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 or 200 mg/m\^2 orally
Study: NCT00005834
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
Study: NCT00887146
Drug: CCNU
Normalized name: CCNU
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: 110 mg/m\^2 orally
Study: NCT00887146
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 8 and 29: 1.4 mg/m\^2 IV
Study: NCT00005834
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 2: 800 mg/d (max dose) PO daily
Study: NCT01791101
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02689167
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02517320
Drug: MT-3995 Low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02517320
Drug: MT-3995 Middle
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02517320
Drug: MT-3995 High
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00444340
Drug: Enbrel (Etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03121833
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Endostatin Injection
Study: NCT02101840
Drug: Apo-Oxycodone CR®
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
Study: NCT00243984
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00239187
Drug: E1 and G1
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein Injection [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00484536
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsules, 500 mg bid (1000 mg/day)
Study: NCT00484536
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Capsules, 500 mg, once daily
Study: NCT00789958
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
Study: NCT02622724
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT00296725
Drug: Imipramine
Normalized name: Imipramine
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
Study: NCT02345824
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK4/6 INHIBITOR
Study: NCT04367025
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab: 200mg,iv drip for 1h,d1,q3w
Study: NCT04367025
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
Study: NCT04367025
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1:40\~60mg Bid, d1\~14, q3w;
Study: NCT01925638
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04583111
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
Study: NCT04583111
Drug: sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
Study: NCT01016665
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20mg and anastrozole 1 mg
Study: NCT02230878
Drug: JNJ-42847922 5 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
Study: NCT02230878
Drug: JNJ-42847922 10 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
Study: NCT02230878
Drug: JNJ-42847922 20 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
Study: NCT02230878
Drug: JNJ-42847922 40 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
Study: NCT03156439
Drug: BIS-001 ER
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Study: NCT02746185
Drug: rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
Study: NCT01521377
Drug: Placebo Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose placebo oral tablet Moxifloxacin
Study: NCT01521377
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose tablet Moxifloxacin (400mg)
Study: NCT01521377
Drug: GSK573719/Vilanterol 125/25mcg
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
Study: NCT01521377
Drug: GSK573719/Vilanterol 500/100mcg
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
Study: NCT01604057
Drug: ZT-034 Low Dose Nasal Spray
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nasal Spray
Study: NCT01604057
Drug: ZT-034 High Dose Nasal Spray
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray
Study: NCT01592032
Drug: Vancomycin antimicrobial-lock solution
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study: NCT01592032
Drug: Teicoplanin antimicrobial-lock solution
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study: NCT01604057
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mcg subcutaneous daily